TY - JOUR
T1 - Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors
AU - Di Stasi, Antonio
AU - Milton, Denái R.
AU - Poon, L. M.
AU - Hamdi, Amir
AU - Rondon, Gabriela
AU - Chen, Julianne
AU - Pingali, Sai R.
AU - Konopleva, Marina
AU - Kongtim, Piyanuch
AU - Alousi, Amin
AU - Qazilbash, Muzaffar H.
AU - Ahmed, Sairah
AU - Bashir, Qaiser
AU - Al-atrash, Gheath
AU - Oran, Betul
AU - Hosing, Chitra M.
AU - Kebriaei, Partow
AU - Popat, Uday
AU - Shpall, Elizabeth J.
AU - Lee, Dean A.
AU - de Lima, Marcos
AU - Rezvani, Katayoun
AU - Khouri, Issa F.
AU - Champlin, Richard E.
AU - Ciurea, Stefan O.
N1 - Publisher Copyright:
© 2014 American Society for Blood and Marrow Transplantation.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) has been performed primarily with an HLA-matched donor. Outcomes of haploidentical transplantation have recently improved, and a comparison between donor sources in a uniform cohort of patients has not been performed. We evaluated outcomes of 227 patients with AML/MDS treated with melphalan-based conditioning. Donors were matched related (MRD) (n=87, 38%), matched unrelated (MUD) (n=108, 48%), or haploidentical (n=32, 14%). No significant differences were found between haploidentical and MUD transplantation outcomes; however, there was a trend for improved outcomes in the MRD group, with 3-year progression-free survival for patients in remission of 57%, 45%, and 41% for MRD, MUD, and haploidentical recipients, respectively (. P=.417). Recovery of T cell subsets was similar for all groups. These results suggest that haploidentical donors can safely extend transplantation for AML/MDS patients without an HLA-matched donor. Prospective studies comparing haploidentical and MUD transplantation are warranted.
AB - Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) has been performed primarily with an HLA-matched donor. Outcomes of haploidentical transplantation have recently improved, and a comparison between donor sources in a uniform cohort of patients has not been performed. We evaluated outcomes of 227 patients with AML/MDS treated with melphalan-based conditioning. Donors were matched related (MRD) (n=87, 38%), matched unrelated (MUD) (n=108, 48%), or haploidentical (n=32, 14%). No significant differences were found between haploidentical and MUD transplantation outcomes; however, there was a trend for improved outcomes in the MRD group, with 3-year progression-free survival for patients in remission of 57%, 45%, and 41% for MRD, MUD, and haploidentical recipients, respectively (. P=.417). Recovery of T cell subsets was similar for all groups. These results suggest that haploidentical donors can safely extend transplantation for AML/MDS patients without an HLA-matched donor. Prospective studies comparing haploidentical and MUD transplantation are warranted.
KW - Acute myeloid leukemia
KW - Fludarabine-melphalan
KW - Haploidentical transplantation
KW - Hematopoietic stem cell transplantation
KW - Myeloablative reduced-intensity conditioning regimen
KW - Myelodysplastic syndromes
KW - Post-transplantation cyclophosphamide
UR - http://www.scopus.com/inward/record.url?scp=84912134520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84912134520&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2014.08.013
DO - 10.1016/j.bbmt.2014.08.013
M3 - Article
C2 - 25263628
AN - SCOPUS:84912134520
SN - 1083-8791
VL - 20
SP - 1975
EP - 1981
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 12
ER -